-
ABOUT USThe company is a professional API manufacturer established and developed by Shijiazhuang No.4 Pharmaceutical Group to actively promote the development strategy of "API + preparation"
-
INNOVATIONDevelops fine, series, high-end API and innovative API intermediates with high added value through overcoming key technologies such as API synthesis to build variety competition advantages.
-
PRODUCTSWith the annual production 500MT of hydroxyethyl starch , 500MT of azithromycin , we are ranking in the API professional enterprises in Hebei Province and even in China .
-
RECRUITGuolong has jointly established engineering laboratories, technology research centers and other high-level innovation platforms with CAS, Zhejiang University, Tianjin University and other universities
-
CONTACTAdhering to the "love the people with quality, formed the base with integrity" business philosophy, is committed to developing the domestic high-end market and the international market.
Guangxiang Pharmaceutical: Building a Model of “Green Pharmaceutical Production” with New Concepts
Category:
Time:2019-12-03
【概要描述】
Shi Si Yao Group’s Hebei Guangxiang Pharmaceutical is seizing the opportunities presented by the coordinated development of the Beijing-Tianjin-Hebei region. Relying heavily on the group’s strong financial resources, robust R&D capabilities, and established brand reputation, the company is investing in the Beijing-Cangzhou Bohai New Area Biopharmaceutical Industrial Park to build a mega-scale pharmaceutical enterprise specializing in active pharmaceutical ingredients, intermediate compounds, and biopharmaceutical formulations.
Shi Si Pharmaceutical Group’s Hebei Guangxiang Pharmaceutical is seizing the opportunities presented by the coordinated development of the Beijing-Tianjin-Hebei region. Relying firmly on the group’s strong financial resources, robust R&D capabilities, and established brand reputation, it is investing in the Beijing-Cangzhou Bohai New Area Biopharmaceutical Industrial Park to build a mega-scale pharmaceutical enterprise specializing in active pharmaceutical ingredients, intermediate compounds, and biopharmaceutical formulations.
The project covers a total area of over 1,000 mu. The first phase occupies 500 mu and has a total construction area of 250,000 square meters. Currently, 160,000 square meters of factory buildings and supporting facilities have been completed, with an investment of nearly 1 billion yuan. The primary products of the first phase include caffeine series, metronidazole, nifedipine, and aminophylline. The second phase will mainly produce a range of products such as azithromycin and arbidol, as well as various biopharmaceutical preparations.
Gao Shuping, Chairperson of Hebei Guangxiang Pharmaceutical, part of the Shisi Pharmaceutical Group, introduced that Guangxiang Pharmaceutical’s flagship caffeine series has adopted advanced automation and information technologies to transform its traditional batch production into continuous, intelligent manufacturing. This has significantly boosted production efficiency, improved product quality and safety levels, and greatly reduced pollutant emissions. At the same time, for the first time, hydrogenation reduction technology has been used in place of the conventional iron powder reduction process, effectively minimizing environmental pollution.
The project is built on the “green pharmaceutical” philosophy, integrating, absorbing, and applying world-class technologies, process techniques, and equipment in the synthesis, reduction, separation, and extraction of active pharmaceutical ingredients. It highlights advantages and features such as energy conservation and environmental protection, intensive efficiency, and safe production. The first-phase environmental protection investment reached 160 million yuan, and for the first time in the industry, advanced technologies such as CWO, MVR, and ozone catalytic oxidation have been adopted, significantly reducing the total COD emissions, improving effluent water quality, and minimizing solid waste generation.
Gao Shuping stated that, with strong support from the CPC Municipal Committee and the Municipal Government of Cangzhou, as well as the Party Working Committee and Management Committee of the Bohai New Area, the project’s construction has been accelerated. Construction officially began in March 2018, and in September 2019, the company obtained the GMP certification and officially started production. After the first phase operates normally, it is expected to generate annual sales revenue of 2.2 billion yuan and annual profits and taxes of 600 million yuan. The company is committed to building a green factory that serves as an industry- and regionally iconic, exemplary model, playing a leading role in the high-quality development of the Bohai New Area in Cangzhou.
(Sun Jiayue Chen Lei)
Keywords:
Next
Recommended
Share to
SERVICE HOTLINE
Zip Code: 052165
Address: No.9 Xingye Street, Gaocheng District, Shijiazhuang City, Hebei Province
Mobile site
E code
Business license